|
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial of CTS-1027 in Combination With Pegylated Interferon
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Human Genome calls hepatitis drug sleeper product
* Zalbin may take big market share from top interferons * Less-frequent dosing could give Zalbin edge * Annual $2 bln interferon market to grow with Zalbin * Could launch both Zalbin, Benlysta this year NEW YORK, Feb 9 (Reuters) - As Human Genome Sciences Inc...
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavir
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus HCV 2010 FEB 8 - (NewsRx.com) Conatus Pharmaceuticals Inc.announced the initiation of a Phase II clinical...
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated ...
Conatus Pharmaceuticals announced the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients SAN DIEGO, CA, USA | January 28, 2010 | Conatus...
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavir
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Report on hepatitis B & C market dynamics in China, South Korea, Taiwan and Turkey
Research and Markets (http://www.researchandmarkets.com/research/65d3a4/stakeholder_insigh) has announced the addition of the "Stakeholder Insight: Hepatitis B & C in Asia - China, South Korea, Taiwan and Turkey" report to their offering.Stakeholder...
|
|
|
Research and Markets: Stakeholder Insight: Hepatitis B & C in Asia - China, South Korea, Taiwan and Turkey Includes Results of Surveys of 180 High-Pre
Research and Markets (http://www.researchandmarkets.com/research/65d3a4/stakeholder_insigh) has announced the addition of the "Stakeholder Insight: Hepatitis B & C in Asia - China, South Korea, Taiwan and Turkey" report to their offering.China, Taiwan,...
|
|
|
Pharmasset Starts Trial of HCV Polymerase Inhibitor PSI-7977 for Genotype 1 Chronic Hepatitis C Patients
Below is an edited excerpt from a Pharmasset press release describing the study and the drug.Princeton, NJ -- January 21, 2010 -- Pharmasset, Inc. (Nasdaq: VRUS) today announces the initiation of a 28-day Phase 2a study with PSI-7977, a chirally pure...
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial In Combination With Pegylated Interferon And Ribavir
Conatus Pharmaceuticals Inc.announced the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients. Antiviral activity, safety and tolerability...
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV
Conatus Pharmaceuticals Inc.announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients. Antiviral activity, safety and...
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
